US/UK/Canada

Share

Contacts

  • Timo Lehtonen

    CEO


    Yrittäjänkulma 5, FI-33710 Tampere, FINLAND
    +358 50 433 8493
    https://bioretec.com/
  • Johanna Salko

    CFO


    Yrittäjänkulma 5, FI-33710 Tampere, Finland
    +358 40 754 8172
    https://bioretec.com/

    • Links

    Quotes

    It is an honor to announce this SAB and integrate these merited leaders of the orthopedic industry with our new RemeOs™ Screw products and material technology development. We are thrilled to have decades of the expertise and impactful accomplishments of SAB members behind us. Their combined resume includes significant professional and academic contributions and influential positions in the global orthopedic community. We are looking forward to this cooperation with our SAB and interesting future activities.
    Timo Lehtonen, CEO of Bioretec
    Pick a time period -
    Tags ( Active)

    Bioretec Ltd’s schedule for financial reporting in 2025

    Bioretec Ltd                           Company announcement                          16 December 2024 at 6.15 p.m. EETIn 2025, Bioretec will publish the following financial reports: · financial statements bulletin for January–December 2024 on Friday 14 February 2025 · financial statements for 2024 on Friday 14 February 2025 · annual report for 2024 during week 11/2025 at the latest · business review for January–March 2025 on Thursday 15 May 2025 · half-year report for January–June 2025 on Thursday 14 August 2025 · business review for January–September 2025 on Thursday 13

    The Finnish Financial Supervisory Authority has imposed a penalty payment on a member of Bioretec's Board of Directors for late notification of managers' transactions

    Bioretec Ltd  Company announcement  12 December 2024 at 6.15 p.m. EETThe Finnish Financial Supervisory Authority (the "FIN-FSA") has imposed a penalty payment of EUR 3,000 on Michael Piccirillo, as a member of Bioretec's Board of Directors and a person discharging managerial responsibilities for the late notifications of transactions in Bioretec's share made in his own account. The decision of the FIN-FSA is not yet legally binding and can be appealed by Michael Piccirillo. Further enquiries Alan Donze, CEO, +1 619 977 5285Johanna Salko, CFO, +358 40 754 8172 Certified adviser

    Correction: Bioretec Ltd – Managers’ transactions – Stephen Industries Inc Oy

    Bioretec Ltd      Managers’ transactions 29 November 2024 at 1.30 p.m. EETThis notice corrects the Management Transaction notice published on 29 November 2024 at 7:45, in which Kustaa Poutiainen was listed as a person subject to the notification requirement. The correct person subject to the notification requirement is Stephen Industries Inc Oy. Correction - Bioretec Oy - Managers' Transactions _________________________________________ Person subject to the notification requirement Name: Stephen Industries Inc Oy Position: Closely associated person (X) Legal person  (1):

    Bioretec Ltd – Managers’ transactions – Poutiainen

    Bioretec Ltd      Managers’ transactions 29 November 2024 at 7.45 a.m. EETBioretec Oy - Managers' Transactions _______________________________________ Person subject to the notification requirement Name: Kustaa Poutiainen Position: Member of the Board/Deputy member  Issuer: Bioretec Oy LEI: 7437008736AG7HY51K13 Notification type: INITIAL NOTIFICATION Reference number: 86452/4/4 ____________________________________________ Transaction date: 2024-11-28 Outside a trading venue Instrument type: SHARE ISIN: FI4000480454 Nature of transaction:

    Bioretec Ltd: 3,000,000 new shares registered with the trade register

    Bioretec Ltd  Company announcement  28 November 2024 at 4.30 p.m. EETTHE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Bioretec Ltd ("Bioretec" or the "Company"), a pioneer in biodegradable orthopedic implants, announced on 27 November 2024 the result of the offering of new shares (the "Placing Shares") in a private placement to institutional and other

    Inside information: Bioretec Ltd successfully completes private placement raising EUR 6 million

    Bioretec Ltd Inside information 27 November 2024 at 10.15 p.m. EETTHE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Bioretec Ltd ("Bioretec" or the "Company"), a pioneer in biodegradable orthopedic implants, hereby announces the result of the offering of new shares (the "Placing Shares") in a private placement to institutional and other qualified investors (

    Inside information: Bioretec Ltd launches an accelerated book-building process to raise approximately EUR 5 million through a private placement of new shares

    Bioretec Ltd  Inside information 27 November 2024 at 6:30 p.m. EETTHE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Bioretec Ltd ("Bioretec" or the "Company"), a pioneer in biodegradable orthopedic implants, hereby announces its intention to issue new shares (the "Placing Shares") in a private placement to institutional and other qualified investors (the "

    Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

    Bioretec Ltd                   Press release             22 November 2024 at 9:30 a.m.EETBioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, is moving ahead with the next phase of the commercialization of its innovative RemeOs™ Trauma Products in the U.S. market. As a continuation to the previously signed logistics agreement with GlobalMed Logistix, Bioretec strengthens now its commercialization efforts by signing a new sales and distribution agreement with Tri-State Biologics (TSB), which is a distributor of medical and surgical products based in

    The commercialization of Bioretec’s RemeOs™ Trauma Screw in the U.S. proceeds with the signing of new logistics agreement

    Bioretec Ltd                   Press release             20 November 2024 at 3:30 p.m. EETBioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, is moving ahead with the next phase of commercializing its innovative RemeOs™ Trauma Products in the U.S. market. Bioretec strengthens its operational efforts by entering into a new logistics agreement with a partner providing customer support services for U.S. operations. This agreement with GlobalMed Logistix (GMLx), a leader in healthcare logistics, will enable the smooth import and distribution of implants

    Bioretec Ltd’s business review January–September 2024: Launch of the RemeOs™ Trauma Screw in the U.S. is proceeding to the next phase, EU authorization in the final stage

    Bioretec Ltd  Company announcement 14 November 2024 at 8:45 a.m.This announcement summarizes Bioretec Ltd’s business review for January–September 2024. The complete business review is attached to this release as a PDF file and available on the company’s website at https://bioretec.com/investors/investors-in-english/releases.   July – September 2024 in brief · Net sales amounted to EUR 685 thousand (7–9/2023: EUR 483 thousand). · The sales margin (excl. other income) was EUR 499 (397) thousand, or 72.9% (82.2%). The main reasons for the lower sales margin percentage were

    Inside information: Bioretec updates its financial targets

    Bioretec Ltd  Company announcement 4 October 2024 at 2:31 p.m. EESTBioretec Ltd announced today, 4 October 2024, that Bioretec's board of directors had decided to update the company's product development strategy by accelerating the product development of the RemeOs™ Spinal Interbody Cage following the granting of Breakthrough Device Designation status by the US Food and Drug Administration on 14 March 2024. Due to the acceleration of the product development of the RemeOs™ Spinal Interbody Cage, Bioretec's Board of Directors has today updated Bioretec's financial targets as follows:

    Inside information: Bioretec updates its product development strategy by accelerating the product development of RemeOs™ Spinal Interbody Cage

    Bioretec Ltd Company announcement 4 October 2024 at 2:30 p.m. EESTBioretec updates its product development strategy by accelerating the product development of the RemeOs™ Spinal Interbody Cage, an innovative medical device engineered from a multifunctional, MRI-compatible, absorbable hybrid composite based on the company's proprietary magnesium alloy. The decision to accelerate the product development of the RemeOs™ Spinal Interbody Cage is based on an evaluation by the company following the granting of Breakthrough Device designation by the US Food and Drug Administration on March 2024.

    Bioretec’s Shareholders' Nomination Board appointed

    Bioretec Ltd   Company announcement      20 September 2024 at 9:00 a.m. (EET)The following persons have been appointed to Bioretec's Shareholders' Nomination Board: Kustaa Poutiainen, Chair and Founder of Stephen Industries Inc Oy as Chair and Karoliina Lindroos, Head of Responsible Investment of Ilmarinen Mutual Pension Insurance Company and Marko Berg, Deputy Investment Officer of University of Helsinki, as members. The Chairman of the Board of Bioretec acts as an expert to the Nomination Board. In accordance with the decision taken by the Annual General Meeting (AGM) held on 26 April

    Bioretec Ltd’s half-year report January–June 2024: RemeOs™ trauma screw controlled launch in the U.S. yielded expected positive clinical results

    Bioretec Ltd  Company announcement 15 August 2024 at 8:00 a.m.This announcement is a summary of Bioretec Ltd’s half-year report January–June 2024. The complete half-year report with tables is attached to this release as a pdf file and available at the company’s web pages at https://bioretec.com/investors/investors-in-english/releases.   April–June 2024 in brief · Net sales increased by 68% and amounted to EUR 1,379 thousand (4–6/2023: EUR 820 thousand). · Sales margin (excl. other income) was EUR 1,033 (609) thousand, or 74.9% (74.3%) of net sales. · Profit (loss) for the

    Inside Information: Update for Bioretec's RemeOs™ Trauma Screw European Marketing Authorization

    Bioretec Ltd     Inside information        27 June 2024 at 10:30 p.m. EETBioretec Ltd., a pioneer in bioresorbable orthopedic implants, announces that according to the information received from the Notified Body (Dekra), its European CE mark market authorization application for the RemeOs™ trauma screw has returned from the expert panel evaluation. Although the previously estimated timeline projected that the CE mark would be obtained by the end of Q2 2024, we now anticipate that it will be issued later beyond this timeline.  The duration of the expert panel evaluation was a maximum of

    Bioretec reports successful clinical outcomes from U.S. controlled launch of RemeOs™ trauma screw: fracture healing confirmed in 100% of surgical procedures

    Bioretec Ltd                    Press release                   19 June 2024 at 9:00 p.m. EESTBioretec Ltd., a pioneer in biodegradable orthopedic implants, is pleased to announce that a number of cases have been performed around the U.S. utilizing the RemeOs™ technology. The follow-up results confirmed successful implantation and fracture healing were achieved in all cases. Surgeons reported very positive feedback in that there is no change to existing surgical technique while operating with an absorbable metal implant for their patients. The added benefit of osteopromotion and bioactivity

    Bioretec Appoints Frank Sarcone as Vice President of Sales for the US and a member of the Management Team

    Bioretec Ltd  Press release 18 June 2024 at 9:00 a.m. EESTBioretec Ltd, a pioneer in biodegradable orthopedic implants, has, as of June 17, 2024, appointed Frank Sarcone as Vice President of Sales for the United States and a member of Bioretec’s Management Team. In his role, Sarcone reports to the company’s CEO. This strategic addition to Bioretec’s leadership team comes as part of the ongoing commitment to driving growth and innovation in the medical device technology industry. Frank Sarcone brings with him a wealth of experience and a remarkable track record in the medical device

    Notification in accordance with chapter 9, section 10 of the Securities Market Act on a change in holdings - Ilmarinen Mutual Pension Insurance Company

    Bioretec Ltd Company announcement 21 May 2024 at 2:30 p.m. EESTBioretec Ltd has on 21 May 2024 received a notification in accordance with the Securities Market Act, according to which the holdings of shares and votes of Ilmarinen Mutual Pension Insurance Company in Bioretec Ltd have before 19 April 2024 crossed the threshold of 5%. The reason for the flagging notification is the amendment to the Securities Market Act, which expanded the flagging obligation to companies listed on the Nasdaq First North Growth Market Finland. Total position of Ilmarinen Mutual Pension Insurance Company

    Notification in accordance with chapter 9, section 10 of the Securities Market Act on a change in holdings (Stephen Industries Inc Oy)

    Bioretec Ltd Company announcement 20 May 2024 at 7:00 p.m. EESTBioretec Ltd has on 20th May 2024 received a notification in accordance with the Securities Market Act, according to which the holdings of shares and votes of Stephen Industries Inc Oy in Bioretec Ltd have before 19 April 2024 crossed the threshold of 10%. The reason for the flagging notification is the amendment to the Securities Market Act, which expanded the flagging obligation to companies listed on the Nasdaq First North Growth Market Finland. Total position of Stephen Industries Inc Oy according to the notification:

    Inside information: Alan Donze has been appointed as Bioretec's new CEO

    Bioretec Ltd    Inside information  20 May 2024 at 6:00 p.m. EESTBioretec Ltd is pleased to announce that Mr. Alan Donze has been appointed CEO of Bioretec as of today, 20 May 2024. He will start in this position immediately. With a distinguished career spanning the banking and medical device industries, Mr. Donze brings a wealth of experience and expertise to the Bioretec organization. Mr. Donze began his career journey in the banking industry, serving as the Vice President of Commercial Lending and Leveraged Finance for a regional predecessor to Chase bank. He left banking to begin his

    Bioretec Ltd’s business review January–March 2024: Controlled launch in the U.S. progresses

    Bioretec Ltd  Company announcement 16 May 2024 at 8:30 a.m.This announcement summarizes Bioretec Ltd’s business review for January–March 2024. The complete business review is attached to this release as a PDF file and available on the company’s website at https://bioretec.com/investors/investors-in-english/releases.   January–March 2024 in brief · Net sales amounted to EUR 682 thousand (1–3/2023: EUR 1,071 thousand). · The sales margin was EUR 478 (718) thousand, or 70.1% (67.0%) of net sales. The sales margin of 2024 includes other income of EUR 60 thousand accrued relating

    Resolutions of Bioretec Ltd´s Annual General Meeting and the constitutive meeting of the Board of Directors

    Bioretec Ltd  Company announcement 26 April 2024 at 12:15 p.m. EESTThe Annual General Meeting of Bioretec Ltd was held on 26 April 2024 in Tampere, Finland. The Annual General Meeting approved the financial statements for the financial year 1 January–31 December 2023 and resolved to discharge the members of the Board of Directors and the CEO from liability for the financial period 1 January–31 December 2023.   The Annual General Meeting resolved in accordance with the proposal of the Board of Directors that the loss of EUR 3,721,314.67 for the financial period 1 January–31 December

    Notice of Annual General Meeting (AGM) of Bioretec Ltd

    Bioretec Ltd                         Company announcement    5 April 2024 at 3:00 p.m. EETThe shareholders of Bioretec Ltd are hereby invited to the Annual General Meeting to be held on 26 April 2024 at 10:00 a.m. (Finnish time) at Bioretec premises in the auditorium of Tampark, at the address Yrittäjänkulma 5, FI-33710 Tampere, Finland.   A shareholder may participate in the Annual General Meeting and exercise their rights at the meeting by way of proxy representation. A proxy representative shall present a dated power of attorney or, in another reliable manner, demonstrate their

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe